Thérapies de Conversion

TPF regimen improves conversion surgery and short-term survival in patients with locally unresectable advanced gastric cancer.

Am J Transl Res . 2025;17 (8) :6068-6079

Résumé

OBJECTIVE: To compare the efficacy and safety of TPF versus FOLFOX regimens in conversion therapy for locally unresectable advanced gastric cancer (LAUGC) and to identify prognostic factors influencing clinical outcomes.METHODS: This retrospective study analyzed 264 LAUGC patients treated with either TPF (n=140) or FOLFOX (n=124) between 2019 and 2021. Primary endpoints were objective response rate (ORR) and 1-year survival; secondary endpoints included conversion surgery rate, toxicity, and 3-year survival. Prognostic factors were evaluated using multivariate Cox regression and time-dependent ROC analyses.RESULTS: The TPF group demonstrated significantly higher ORR (P=0.01) and disease control rate (DCR; P

Tous les articles